Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Year: 2023
Type: other
Abstract: Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving merestinib + LY2874455 in Cohort 2 (n=8, red line). Geometric mean is displayed. Error bars denote standard error. * signifies p < 0.05. B, Plasma levels of merestinib (first column) and its metabolites LSN2800870 and LSN2887652 (second and third columns, respectively) in patients receiving merestinib monotherapy (first row) and merestinib + LY2874455 (second row). C, Plasma levels of LY2874455 in patients receiving merestinib + LY2874455. Abbreviations: Cohort 1 = patients receiving single-agent merestinib; Cohort 2 = patients receiving merestinib + LY2874455.
Authors: Evan C. Chen, Helen Gandler, Isidora Tošić, Geoffrey G. Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J. DeAngelo, Ilene Galinsky, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna Neuberg, A. Thomas Look, Richard M. Stone, David A. Frank, Jacqueline S. Garcia
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361956339